This study aimed to identify the genetic cause of a new multiple congenital anomalies syndrome observed in three individuals from two unrelated families.
Clinical assessment was conducted prenatally and at different postnatal stages. Genetic studies included exome sequencing (ES) combined with single-nucleotide polymorphism (SNP) array based homozygosity mapping and trio ES. Dermal fibroblasts were used for functional assays.
A clinically recognizable syndrome characterized by severe developmental delay, variable brain anomalies, congenital heart defects, dysmorphic facial features, and a distinctive type of synpolydactyly with an additional hypoplastic digit between the fourth and fifth digits of hands and/or feet was identified. Additional features included eye abnormalities, hearing impairment, and electroencephalogram anomalies. ES detected different homozygous truncating variants in MAPKAPK5 in both families. Patient-derived cells showed no expression of MAPKAPK5 protein isoforms and reduced levels of the MAPKAPK5-interacting protein ERK3. F-actin recovery after latrunculin B treatment was found to be less efficient in patient-derived fibroblasts than in control cells, supporting a role of MAPKAPK5 in F-actin polymerization.
Our data indicate that loss-of-function variants in MAPKAPK5 result in a severe developmental disorder and reveal a major role of this gene in human brain, heart, and limb development.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Data supporting this paper are contained within the article and Supplementary information. Any additional data not compromised by ethical issues will be available upon request.
Plotnikov, A., Zehorai, E., Procaccia, S. & Seger, R. The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim. Biophys. Acta 1813, 1619–1633 (2011).
Cargnello, M. & Roux, P. P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol. Mol. Biol. Rev. 75, 50–83 (2011).
Ni, H., Wang, X. S., Diener, K. & Yao, Z. MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase. Biochem. Biophys. Res. Commun. 243, 492–496 (1998).
Seternes, O. M. et al. Both binding and activation of p38 mitogen-activated protein kinase (MAPK) play essential roles in regulation of the nucleocytoplasmic distribution of MAPK-activated protein kinase 5 by cellular stress. Mol. Cell. Biol. 22, 6931–6945 (2002).
New, L., Jiang, Y. & Han, J. Regulation of PRAK subcellular location by p38 MAP kinases. Mol. Biol. Cell. 14, 2603–2616 (2003).
New, L. et al. PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J. 17, 3372–3384 (1998).
Aberg, E. et al. Regulation of MAPK-activated protein kinase 5 activity and subcellular localization by the atypical MAPK ERK4/MAPK4. J. Biol. Chem. 281, 35499–35510 (2006).
Kant, S. et al. Characterization of the atypical MAPK ERK4 and its activation of the MAPK-activated protein kinase MK5. J. Biol. Chem. 281, 35511–35519 (2006).
Schumacher, S. et al. Scaffolding by ERK3 regulates MK5 in development. EMBO J. 23, 4770–4779 (2004).
Seternes, O. M. et al. Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a novel signal transduction pathway. EMBO J. 23, 4780–4791 (2004).
Deleris, P. et al. Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5 signaling pathway. J. Biol. Chem. 286, 6470–6478 (2011).
Estan, M. C. et al. Recessive mutations in muscle-specific isoforms of FXR1 cause congenital multi-minicore myopathy. Nat. Commun. 10, 797 (2019).
Holtgrewe, M., et al. VarFish: comprehensive DNA variant analysis for diagnostics and research. Nucl. Acids Res. https://doi.org/10.1093/nar/gkaa241 (2020).
Ehmke, N. et al. Biallelic variants in KYNU cause a multisystemic syndrome with hand hyperphalangism. Bone. 133, 115219 (2020).
Kosmas, K. et al. CAP2 is a regulator of the actin cytoskeleton and its absence changes infiltration of inflammatory cells and contraction of wounds. Eur. J. Cell. Biol. 94, 32–45 (2015).
Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 581, 434–443 (2020).
Nagy, E. & Maquat, L. E. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem. Sci. 23, 198–199 (1998).
Ronkina, N. et al. Comparative analysis of two gene-targeting approaches challenges the tumor-suppressive role of the protein kinase MK5/PRAK. PLoS One 10, e0136138 (2015).
Tak, H. et al. 14-3-3epsilon inhibits MK5-mediated cell migration by disrupting F-actin polymerization. Cell. Signal. 19, 2379–2387 (2007).
Shi, Y. et al. Elimination of protein kinase MK5/PRAK activity by targeted homologous recombination. Mol. Cell. Biol. 23, 7732–7741 (2003).
Sun, P. et al. PRAK is essential for ras-induced senescence and tumor suppression. Cell. 128, 295–308 (2007).
Brand, F. et al. The extracellular signal-regulated kinase 3 (mitogen-activated protein kinase 6 [MAPK6])-MAPK-activated protein kinase 5 signaling complex regulates septin function and dendrite morphology. Mol. Cell. Biol. 32, 2467–2478 (2012).
Svitkina, T. The actin cytoskeleton and actin-based motility. Cold Spring Harb. Perspect. Biol. 10, a018267 (2018).
Fischer, M., Kaech, S., Knutti, D. & Matus, A. Rapid actin-based plasticity in dendritic spines. Neuron. 20, 847–854 (1998).
Nawaito, S. A. et al. MK5 haplodeficiency attenuates hypertrophy and preserves diastolic function during remodeling induced by chronic pressure overload in the mouse heart. Am. J. Physiol. Heart Circ. Physiol. 313, H46–H58 (2017).
Nawaito, S. A. et al. MK5 haplodeficiency decreases collagen deposition and scar size during post-myocardial infarction wound repair. Am. J. Physiol. Heart Circ. Physiol. 316, H1281–H1296 (2019).
Chen, G., Hitomi, M., Han, J. & Stacey, D. W. The p38 pathway provides negative feedback for Ras proliferative signaling. J. Biol. Chem. 275, 38973–38980 (2000).
Yoshizuka, N. et al. PRAK suppresses oncogenic ras-induced hematopoietic cancer development by antagonizing the JNK pathway. Mol. Cancer Res. 10, 810–820 (2012).
Tajan, M., Paccoud, R., Branka, S., Edouard, T. & Yart, A. The RASopathy family: consequences of germline activation of the RAS/MAPK pathway. Endocr. Rev. 39, 676–700 (2018).
Sobreira, N., Schiettecatte, F., Valle, D. & Hamosh, A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum. Mutat. 36, 928–930 (2015).
Moens, U. & Kostenko, S. Structure and function of MK5/PRAK: the loner among the mitogen-activated protein kinase-activated protein kinases. Biol. Chem. 394, 1115–1132 (2013).
We are grateful to patients and their parents for their participation in this study. The work at IIB was financially supported by the Spanish Ministry of Science, Innovation and Universities (PID2019-105620RB-I00/AEI/10.13039/501100011033 and SAF2016‐75434‐R (AEI/FEDER, UE). The authors also acknowledge the GeneMatcher tool30 which allowed the identification of these two families and Manuel Holtgrewe, Core Unit Bioinformatics of the Berlin Institute of Health (BIH), for processing of the exome data of family 2.
Parental consent was obtained for all clinical and molecular studies of this report and for the publication of clinical photographs. All studies and investigations were performed according to the declaration of Helsinki principles of medical research involving human subjects and the study was approved by institutional Ethics Committees of National Research Centre, Hospital La Paz-CSIC and Charité-Universitaetsmedizin (EA2/140/17).
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Horn, D., Fernández-Núñez, E., Gomez-Carmona, R. et al. Biallelic truncating variants in MAPKAPK5 cause a new developmental disorder involving neurological, cardiac, and facial anomalies combined with synpolydactyly. Genet Med (2021). https://doi.org/10.1038/s41436-020-01052-2